GlobeNewswire Inc.··NaOKYO Pharma's Neuropathic Eye Pain Therapy Earns ARVO 2026 Presentation Slot
OKYO Pharma's urcosimod earns ARVO 2026 presentation slot for neuropathic eye pain therapy. Phase 2a data shows pain reduction and quality-of-life improvements; Phase 2b/3 trial planned for 2026.
OKYOclinical trial resultsneuropathic corneal pain